Imatinib

In the US, Imatinib (imatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome, Myelodysplastic Diseases, Myeloproliferative Disorders and Systemic Mastocytosis.

US matches:

• Imatinib


• Imatinib Mesylate

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE01

CAS registry number (Chemical Abstracts Service)

0152459-95-5

Chemical Formula

C29-H31-N7-O

Molecular Weight

493

Therapeutic Category

Antineoplastic agent

Chemical Names

alpha-(4-methyl-1-piperazinyl)-3'-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-p-toluidide- (WHO)

Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-

Foreign Names

• Imatinibum (Latin)
• Imatinib (German)
• Imatinib (French)
• Imatinib (Spanish)

Generic Names

• Imatinib (OS: BAN)
• CGP 57148 (IS)
• Imatinib Mesilate (OS: BAN)
• CGP 57148B (IS: Novartis)
• chronic myeloid leukemia (IS: CML)
• CML (IS)
• Imatinib Mesylate (IS)
• STI 571 (IS: Novartis)

Brand Names

• Glivec
  Novartis, Tunisia; Novartis, Turkey



• Mitinab
  Glenmark, India



• Enliven
  Orion, Bangladesh



• Gleevec
  Novartis, Canada; Novartis, Jordan; Novartis, Japan; Novartis, Syria; Novartis, United States; Novartis, South Africa



• Glivec
  Novartis, Argentina; Novartis, Australia; Novartis, Bosnia & Herzegowina; Novartis, Bangladesh; Novartis, Belgium; Novartis, Bulgaria; Novartis, Bahrain; Novartis, Brazil; Novartis, Switzerland; Novartis, Chile; Novartis, China; Novartis, Colombia; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Ecuador; Novartis, Spain; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Georgia; Novartis, Greece; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Iceland; Novartis, Italy; Novartis, Japan; Novartis, Sri Lanka; Novartis, Luxembourg; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Philippines; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Serbia; Novartis, Russian Federation; Novartis, Sweden; Novartis, Singapore; Novartis, Slovenia; Novartis, Slovakia; Novartis, Thailand; Novartis, Taiwan; Novartis, Venezuela; Novartis, Vietnam; Novartis Europharm, Austria; Novartis Pharmaceuticals, Peru



• Imatib
  Grey Inversiones, Peru



• Zoleta
  Ranbaxy, India

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.